Dekkers Olaf M, Mummery Christine L, Rabelink Ton J
Departments of Clinical Epidemiology, Medicine, and
Anatomy and Developmental Biology, Leiden University Medical Center, Leiden, The Netherlands.
Stem Cells Transl Med. 2014 Nov;3(11):1259-61. doi: 10.5966/sctm.2014-0125. Epub 2014 Sep 17.
Thousands of patients and placebo-treated controls have been included in many clinical trials of stem cell therapy over the last decade or so, but often the study groups have been small. Their scientific value may therefore be limited and their ethical justification questionable. Would "crowd sourcing" for data sharing be a means of increasing the collective value of clinical trials? Here, we make a case for open access of all data emerging from stem cell studies (trials but also observational studies) independent of whether they are investigator-initiated or commercially driven.
在过去十年左右的时间里，数千名患者和接受安慰剂治疗的对照组被纳入了许多干细胞治疗的临床试验，但研究组规模往往较小。因此，它们的科学价值可能有限，其伦理合理性也值得质疑。数据共享的“众包”会是提高临床试验集体价值的一种方式吗？在此，我们主张开放获取干细胞研究（试验以及观察性研究）产生的所有数据，无论这些研究是由研究者发起还是商业驱动。
